MedTrace Logo

The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART

NCT04612452 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2820

Last updated 2023-03-24

No results posted yet for this study

Summary

This is a prospective observational cohort study of 2820 patients on first-line ART switching to a DTG-based first-line regimen, according to the standard of care. The study is conducted in Malawi and Zambia, in ART programs that participate in the IeDEA collaboration. Sequencing will be done on blood samples of patients with a viral load above 400 copies/mL to identify mutations.

Conditions

  • Hiv
  • Drug Resistancy
  • Virologic Failure

Sponsors & Collaborators

  • University of KwaZulu

    collaborator OTHER

  • Lighthouse Trust

    collaborator OTHER

  • Centre for Infectious Disease Research in Zambia

    collaborator OTHER

  • University of Bern

    lead OTHER

Principal Investigators

  • Matthias Egger, Prof. · University of Berne

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-05
Primary Completion
2023-03-22
Completion
2023-03-22

Countries

  • Malawi
  • Zambia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04612452 on ClinicalTrials.gov